Sunshine Biopharma Inc. (SBFM) stock
SBFMNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SBFMW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 10/30
$2.54−0.06 (-2.31%)
Close on Nov 17, 2026Market cap $9.85MP/E –Yield –
Sunshine Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
Sunshine Biopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $237.75K, down 65.4% year over year. For fiscal 2025 it was $604.31K, down 35.3% from the year before. Over ten years it grew 52.9% a year on average. The highest annual figure on record is $1.86M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $604.31K | -35.3% |
| FY2024 | Dec 31, 2024 | $933.90K | -49.7% |
| FY2023 | Dec 31, 2023 | $1.86M | +128.6% |
| FY2022 | Dec 31, 2022 | $811.86K | +20.8% |
| FY2021 | Dec 31, 2021 | $672.21K | +38801.0% |
| FY2020 | Dec 31, 2020 | $1.73K | -88.6% |
| FY2019 | Dec 31, 2019 | $15.20K | +18.8% |
| FY2018 | Dec 31, 2018 | $12.80K | – |
| FY2017 | Dec 31, 2017 | $0 | -100.0% |
| FY2016 | Dec 31, 2016 | $32.79K | +278.8% |
| FY2015 | Dec 31, 2015 | $8.66K | -97.4% |
| FY2014 | Dec 31, 2014 | $327.00K | +138.0% |
| FY2013 | Dec 31, 2013 | $137.40K | +7412.3% |
| FY2012 | Dec 31, 2012 | $1.83K | -98.7% |
| FY2011 | Dec 31, 2011 | $142.65K | – |
| FY2010 | Dec 31, 2010 | $0 | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.22K | -93.3% |
| Q1 FY2026 | Mar 31, 2026 | $31.72K | -85.3% |
| Q4 FY2025 | Dec 31, 2025 | $73.50K | -50.8% |
| Q3 FY2025 | Sep 30, 2025 | $119.30K | -5.6% |
| Q2 FY2025 | Jun 30, 2025 | $196.23K | -55.0% |
| Q1 FY2025 | Mar 31, 2025 | $215.28K | -3.0% |
| Q4 FY2024 | Dec 31, 2024 | $149.27K | -81.7% |
| Q3 FY2024 | Sep 30, 2024 | $126.36K | -46.9% |
| Q2 FY2024 | Jun 30, 2024 | $436.24K | +18.4% |
| Q1 FY2024 | Mar 31, 2024 | $222.03K | -48.7% |
| Q4 FY2023 | Dec 31, 2023 | $816.33K | +1854.7% |
| Q3 FY2023 | Sep 30, 2023 | $238.01K | -34.3% |
| Q2 FY2023 | Jun 30, 2023 | $368.57K | +702.2% |
| Q1 FY2023 | Mar 31, 2023 | $432.93K | +19.7% |
| Q4 FY2022 | Dec 31, 2022 | $41.76K | -54.2% |
| Q3 FY2022 | Sep 30, 2022 | $362.50K | +62.9% |
| Q2 FY2022 | Jun 30, 2022 | $45.94K | -76.0% |
| Q1 FY2022 | Mar 31, 2022 | $361.65K | +116.8% |
| Q4 FY2021 | Dec 31, 2021 | $91.20K | +5177.7% |
| Q3 FY2021 | Sep 30, 2021 | $222.47K | – |
| Q2 FY2021 | Jun 30, 2021 | $191.76K | – |
| Q1 FY2021 | Mar 31, 2021 | $166.79K | – |
| Q4 FY2020 | Dec 31, 2020 | $1.73K | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | -100.0% |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
| Q1 FY2020 | Mar 31, 2020 | $0 | -100.0% |
| Q4 FY2019 | Dec 31, 2019 | $0 | – |
| Q3 FY2019 | Sep 30, 2019 | $15.20K | – |
| Q2 FY2019 | Jun 30, 2019 | $0 | – |
| Q4 FY2018 | Dec 31, 2018 | $12.80K | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
| Q3 FY2017 | Sep 30, 2017 | $0 | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
| Q4 FY2016 | Dec 31, 2016 | $0 | – |
| Q3 FY2016 | Sep 30, 2016 | $0 | – |
See a number that looks wrong?